Axovant Gene Therapies (NASDAQ:AXGT) Raised to “Buy” at ValuEngine
AXGT has been the topic of several other reports. Guggenheim initiated coverage on Axovant Gene Therapies in a report on Friday, February 15th. They set a buy rating and a $56.00 target price on the stock. HC Wainwright reissued a buy rating and issued a $56.00 price objective on shares of Axovant Gene Therapies in a report on Tuesday, March 12th. JMP Securities raised their price objective on Axovant Gene Therapies from $8.00 to $28.00 and gave the company an outperform rating in a report on Thursday, June 6th. Cowen reissued a hold rating on shares of Axovant Gene Therapies in a report on Wednesday, May 1st. Finally, Chardan Capital raised Axovant Gene Therapies from a neutral rating to a buy rating and set a $32.00 price objective on the stock in a report on Monday, March 11th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $35.50.
Shares of NASDAQ:AXGT opened at $5.12 on Friday. Axovant Gene Therapies has a 52-week low of $3.81 and a 52-week high of $30.96. The stock has a market capitalization of $116.63 million, a PE ratio of -0.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.63 and a quick ratio of 2.02.
An institutional investor recently bought a new position in Axovant Gene Therapies stock. Marshall Wace LLP purchased a new position in Axovant Gene Therapies Ltd (NASDAQ:AXGT) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 204,869 shares of the company’s stock, valued at approximately $272,000. Marshall Wace LLP owned approximately 0.90% of Axovant Gene Therapies as of its most recent filing with the Securities & Exchange Commission.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
See Also: Beta
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.